|
Company:
|
DENALI THERAPEUTICS INC. (DNLI)
|
|
Form Type:
|
4
|
|
Filing Date:
|
1/7/2022
|
|
CIK:
|
0001714899
|
|
Address:
|
161 OYSTER POINT BLVD.
|
|
City, State, Zip:
|
SOUTH SAN FRANCISCO, California 94080
|
|
Telephone:
|
(650) 866-8548
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$31.51
|
Change:
-0.01 (-0.03%)
|
Trade Time:
10:10 AM EST
|
Market Cap:
$4.31B
|
|
|
|
|
|
|
Description of Business
|
|
Our goal is to discover, develop and deliver therapeutics to defeat
degeneration.
We are a clinical stage biopharmaceutical company developing a broad portfolio
of product candidates engineered to cross the blood-brain barrier ("BBB") for
neurodegenerative diseases and lysosomal storage diseases. We have a diversified
and differentiated portfolio of both small molecule and biotherapeutic
medicines, comprising seven product candidates in clinical development across
eight indications as well as more than a dozen preclinical therapeutic
candidates. Each of our programs has been engineered for efficient delivery
across the BBB to increase drug exposure in the brain after systemic
administration.
|
|
|
|